Introduction
============

The ether-à-go-go (Eag) superfamily of voltage-gated K^+^ channels comprises three evolutionary conserved families that share high sequence homology: Ether-à-go-go (Eag; K~v~10), ether-à-go-go-related-gene (Erg; K~v~11) and ether-à-go-go-gene-like (Elk; K~v~12) channels ([@B2]). The best-studied member, K~v~11.1 (the human isoform is referred to as HERG channel) mediates rapidly activating K^+^ current I~Kr~ in cardiac myocytes determining heart action potential duration ([@B39]). Accordingly, loss of K~v~11.1 channel function through mutations or drug treatment causes cardiac arrhythmia and sudden death in humans ([@B8]; [@B39]; [@B50]). K~v~11 channels also mediate important K^+^ currents in neurons of the auditory brainstem ([@B15]), the olfactory bulb ([@B16]) and the midbrain ([@B18]). K~v~10.1 channels regulate cell cycle progression and proliferation ([@B38]; [@B51]), and are frequently overexpressed in human cancers with poor prognosis ([@B33]). K~v~10.1 channel mutations cause developmental disorders and epilepsy ([@B21]; [@B43]).

In contrast to K~v~10 and K~v~11 channels, only little information on physiological relevance is available for the three members of the K~v~12 family that are expressed predominantly in neurons ([@B10]; [@B42]; [@B29]; [@B49]; [@B37]; [@B57]). K~v~12.2 channels regulate excitability in pyramidal neurons of hippocampus in mice ([@B56]), but no native current component could be attributed to K~v~12.1 and K~v~12.3 subunits despite expression of their mRNA transcripts in several brain areas ([@B42]; [@B29]; [@B37]; [@B57]). We consider that K~v~12.1/K~v~12.3-mediated currents in neurons were overlooked so far due to insufficient knowledge on biophysical properties and lack of specific pharmacological tools.

Recently, it was shown that K~v~12.1 channels exhibit mode shift of activation (also termed pre-pulse facilitation or voltage-dependent potentiation) ([@B25]; [@B9]). Mode shift denotes time-dependent stabilization of the voltage sensor domain in a "relaxed" open state after prolonged channel activation through depolarized (conditioning) membrane potentials ([@B3]; [@B53]). It manifests by slowing of deactivation and a shift of voltage dependence to hyperpolarized potentials ([@B25]; [@B9]). Accordingly, when measured with routine voltage clamp protocols (e.g., holding potentials of -60 mV) human K~v~12.1 channels mediate "conventional" K^+^ currents that activate similar to many other K~v~ channels with voltages at half-maximal activation of around -30 mV (c.f. **Figure [1](#F1){ref-type="fig"}**) ([@B25]). These currents could easily go unnoticed in cell types expressing different endogenous K^+^ currents. Taking into account their mode shift, appropriate voltage protocols (e.g., depolarized holding potentials) may uncover K~v~12-mediated currents. However, it remains to be explored whether mode shift can be detected in cells expressing various K^+^ currents and whether it may be employed to identify native K~v~12.1 channels. Mode shift is not an exclusive feature of K~v~12.1 channels, but has been demonstrated also for voltage-gated Na^+^ channels ([@B3]), HCN ([@B26]; [@B5]), *Shaker* ([@B32]; [@B48]), and K~v~11.1 (Erg1) channels ([@B34]; [@B47]; [@B11]). Nevertheless, it may constitute a prominent hallmark to distinguish K~v~12 channels from other K^+^ current components in native tissue.

![Voltage-dependent mode shift of human K~v~12.1 channels. **(A)** Representative patch clamp recording of a CHO cell transiently transfected with human K~v~12.1 channels measured with the indicated voltage protocol. **(B)** Representative tail currents elicited at --120 mV after activating pulses of --60 mV (black) and +10 mV (red). Currents were normalized to maximum amplitude for visualization of deactivation kinetics (currents from recording shown in **A**). **(C)** Tail current deactivation was best described by double exponential kinetics: Tau1 and tau2 were derived from double-exponential fits to the decaying phase of tail currents (voltage protocols as in **A**). Deactivation slowed down with channel activation at more depolarized potentials. **(D--F)** When K~v~12.1 channels were activated at 0 mV for different time intervals, **(E)** tail current amplitudes increased and **(F)** deactivation slowed-down with pre-pulse duration. Tail current increase and slowing of deactivation saturated at a pulse duration of about 200 ms and 400--500 ms, respectively (**D** shows a representative recording). **(G--I)** Analysis of voltage dependence of recombinant K~v~12.1 channels. **(G)** Voltage protocols consisted of a 200 ms conditioning potential step to --120 mV (blue), --60 mV (black), 0 mV (red), or +40 mV (orange), followed by 600 ms activating pulse potentials from --140 to +10 mV (10 mV increments). In these experiments, tail currents were elicited either at --120 mV or at 0 mV (for representative recordings see Supplementary Figures [1A,C](#SM1){ref-type="supplementary-material"}). **(H)** Summary of voltage dependence of human K~v~12.1 channels derived from Boltzmann fits to individual recordings as shown in Supplementary Figures [1A,C](#SM1){ref-type="supplementary-material"} (solid line represents a Boltzmann fit to averaged data). Depolarized conditioning potentials of +40 and 0 mV induced a large shift of voltage dependence to hyperpolarized potentials. **(I)** shows mean *V*~h~ of channel activation in dependence of conditioning potentials (derived from fits shown in **H**). **(J,K)** Upon extension of the activating pulses from 600 ms (filled black squares) to 4000 ms (open black squares), voltage dependence of recombinant K~v~12.1 channels was not significantly changed when measured after a conditioning pulse of --60 mV. However, extension of the activating pulse to 4000 ms significantly shifted voltage dependence of K~v~12.1 channels to depolarized potentials after conditioning voltage of 0 mV (*P* ≤ 0.01; open red squares). For data shown in **(J)** eight independent recordings were averaged (each cell measured with all four voltage protocols). There was no significant difference between corresponding data in **(J,K)** and **(H,I)** (conditioning potential --60 mV, 600 ms).](fnmol-11-00011-g001){#F1}

Here we describe biophysical and pharmacological properties of K~v~12.1 channels and demonstrate straightforward experimental protocols that may be employed to identify K~v~12 currents in neurons. We show, that these properties allowed detection of K~v~12.1-mediated currents in cells expressing a variety of different K^+^ channels. Our findings may be utilized to identify physiological roles of K~v~12.1 channels.

Results
=======

Voltage-Dependent Mode Shift of Human K~v~12.1 Channels
-------------------------------------------------------

Mode shift of human K~v~12.1 channels was recently demonstrated ([@B25]), but a detailed characterization is currently not available. In order to identify exclusive properties of human K~v~12.1 channels, we thus set out with detailed biophysical analysis of these channels in an overexpression system. In CHO cells, activation of K~v~12.1 channels through depolarizing voltage steps produced robust outwardly rectifying currents (**Figure [1A](#F1){ref-type="fig"}**) ([@B57]; [@B25]; [@B9]). Channel deactivation at hyperpolarized potentials was best described by double exponential kinetics, and deactivation slowed down with more depolarized pre-potentials (**Figures [1B,C](#F1){ref-type="fig"}**). When we activated K~v~12.1 channels at 0 mV for different time intervals, tail current amplitudes increased (**Figures [1D,E](#F1){ref-type="fig"}**) and deactivation slowed down with the duration of the pre-pulse (**Figure [1F](#F1){ref-type="fig"}**). Tail current increase and slowing of deactivation saturated at a pulse duration of about 200 ms and 400--500 ms, respectively.

We then analyzed voltage dependence of human K~v~12.1 channels with voltage protocols established previously to study mode shift of related K~v~11.1 ([@B47]). We applied depolarizing holding potentials (conditioning potentials; 200 ms) before a series of activating voltage steps (pulse potentials from -140 mV to +10 mV; 600 ms) (**Figure [1G](#F1){ref-type="fig"}** and Supplementary Figures [1A](#SM1){ref-type="supplementary-material"}--[C](#SM1){ref-type="supplementary-material"}). To minimize time intervals at hyperpolarized potentials that may counteract mode shift (c.f. [@B52]), we at start recorded tail currents at correspondingly depolarized potentials (**Figures [1G](#F1){ref-type="fig"}--[I](#F1){ref-type="fig"}**). In these experiments, amplitudes of K~v~12.1-mediated outward currents were similar irrespective of conditioning potentials. This indicated that comparable steady-state channel activation was reached with all voltage protocols (Supplementary Figures [1A](#SM1){ref-type="supplementary-material"}--[C](#SM1){ref-type="supplementary-material"}). After a conditioning potential of -60 mV, voltage dependence of K~v~12.1 channels also did not change relevantly upon extension of the activating steps to 4000 ms (**Figures [1J,K](#F1){ref-type="fig"}**). This additionally demonstrated that steady-state activation of K~v~12.1 channels was already reached by activating pulses as short as 600 ms. For 600 ms activating pulses, half-maximal voltages of activation (*V*~h~) were -29.3 ± 2.3 mV and -24.1 ± 1.6 mV for negative conditioning potentials of -120 mV or -60 mV, respectively (*n* = 7; 600 ms activating pulses; **Figures [1H,I](#F1){ref-type="fig"}**). When cells were held at depolarized conditioning pulses of 0 mV or +40 mV, *V*~h~ was -85.3 ± 0.9 mV and -87.6 ± 0.8 mV, respectively (**Figures [1H,I](#F1){ref-type="fig"}**; 600 ms activating pulses). In these experiments, slope factors derived from Boltzmann fits to the recordings changed from -15.7 ± 0.7 mV (conditioning pulse of -120 mV) and -16.4 ± 0.9 mV (-60 mV) to -8.6 ± 0.1 mV (0 mV) and -8.9 ± 0.6 (+40 mV) (*n* = 7; Supplementary Figure [1D](#SM1){ref-type="supplementary-material"}; 600 ms activating pulses). Accordingly, depolarizing conditioning potentials induced a large shift of voltage dependence by about -60 mV, and the full shift occurred across a potential range of 60 mV (between holding potentials of -60 and 0 mV). In analogous experiments, the same conditioning voltages shifted *V*~h~ of related K~v~11.1 channels from -6.8 ± 4.4 mV (conditioning voltage -60 mV) to -62.4 ± 1.5 (conditioning voltage +40 mV; *n* = 7; **Figures [2A,B](#F2){ref-type="fig"}**), consistent with a previous report ([@B47]).

![K~v~12.1 are not sensitive to extracellular Na^+^. **(A)** Representative recordings from a CHO cell transiently transfected with K~v~11.1 under control conditions (left) and after removal of external Na^+^ (right). **(B)** K~v~11.1 channels exhibit mode shift of activation, as previously reported. After conditioning potential of +40 mV voltage dependence of K~v~11.1 channels shifted to hyperpolarized potentials, compared to conditional potential of --60 mV \[solid lines represent a Boltzmann fit to averaged data; from recordings as shown in **(A)**\]. Upon removal of extracellular Na^+^, voltage dependence of K~v~11.1 shifted to hyperpolarized potentials after conditioning potentials of --60 and +40 mV. **(C)** Shows averaged shifts of *V*~h~ (Δ*V*~h~) for conditional potentials of --60 and +40 mV after removal of extracellular Na^+^. **(D--F)** Recombinant K~v~12.1 channels are insensitive to extracellular Na^+^. **(D)** Representative recordings of K~v~12.1-mediated currents under control conditions (left) and in absence of extracellular Na^+^ (right). **(E)** Summary of voltage dependence of K~v~12.1 channels derived from experiments presented in **(D)**. Note that neither current amplitudes nor voltage dependence of K~v~12.1 channels were affected by removal of extracellular Na^+^. **(F)** shows that removal of extracellular Na^+^ did not shift *V*~h~ (Δ*V*~h~) of activation of K~v~12.1 channels. In these experiments, Na^+^ in the extracellular solution was replaced by NMDG without changing extracellular K^+^ concentration.](fnmol-11-00011-g002){#F2}

We next tested whether mode shift was sensitive to the employed voltage protocol. Therefore, we again applied 200 ms depolarized conditioning pulses, but this time we extended the activating pulses to 4000 ms (**Figures [1J,K](#F1){ref-type="fig"}**). When in these experiments cells were held at conditioning pulses of -60 and 0 mV, *V*~h~ was -43.3 ± 2.5 mV and -66.8 ± 1.5 mV, respectively (**Figures [1J,K](#F1){ref-type="fig"}**). Thus, mode shift of K~v~12.1 channels was readily induced also when activating the channels for 4000 ms. However, the extent of mode shift was significantly reduced in these experiments compared to experiments with 600 ms activating pulses (**Figure [1K](#F1){ref-type="fig"}**; *P* ≥ 0.01), i.e., increased time intervals at hyperpolarized holding potentials during these protocols presumably counteracted development of mode shift. Similarly, the extent of mode shift was reduced when we activated channels for 600 ms after conditioning pulses of -60 and 0 mV, but recorded tail currents at hyperpolarized holding potentials (-120 mV; Supplementary Figures [1E,F](#SM1){ref-type="supplementary-material"}), i.e., we introduced additional hyperpolarizing potentials after every activating pulse. Thus, also in these experiments hyperpolarizing holding potentials between the conditioning pulses reduced the expression of mode shift.

Taken together, human K~v~12.1 channels exhibited significant voltage-dependent mode shift that in response to depolarized holding potentials manifested by slowed channel deactivation and by a large hyperpolarizing shift of voltage dependence. This mode shift of K~v~12.1 channels can be induced robustly employing different voltage protocols, but the extent of mode shift significantly varies with duration of hyperpolarized holding potentials.

In Contrast to K~v~11.1, K~v~12.1 Channels Are Insensitive to Extracellular Na^+^
---------------------------------------------------------------------------------

Inhibition of K~v~11 channels by extracellular Na^+^ is well established ([@B31]; [@B46]) and a hallmark used to identify K~v~11-mediated currents in neurons (e.g., [@B15]). In control experiments, replacement of extracellular Na^+^ with NMDG without altering extracellular K^+^ concentration slightly increased K~v~11.1-mediated outward currents (**Figure [2A](#F2){ref-type="fig"}**), as previously reported ([@B31]). Upon removal of extracellular Na^+^, activation voltage range of K~v~11.1 channels conditioned at -60 and +40 mV shifted to hyperpolarized potentials by -24.4 ± 1.5 mV and -13.9 ± 0.7 mV, respectively (*n* = 7; **Figures [2B,C](#F2){ref-type="fig"}**). Accordingly, overall mode shift of voltage dependence was attenuated from -55.7 ± 4.4 mV under control conditions to -45.1 ± 3.5 mV in absence of extracellular Na^+^ (*n* = 7; *P* ≤ 0.05). We then tested whether related K~v~12.1 channels also exhibited such Na^+^ sensitivity. We found that neither current amplitudes nor voltage dependence of K~v~12.1 channels were affected by removal of extracellular Na^+^ (**Figures [2D](#F2){ref-type="fig"}--[F](#F2){ref-type="fig"}**). Consequently, the extent of mode shift was also insensitive to changes of the Na^+^ concentration. To conclude, despite the high similarity in mode shift behavior, the absence of Na^+^ sensitivity in K~v~12.1 channels distinguishes K~v~11.1-mediated currents from K~v~12.1.

K~v~12.1 Channels Are Not Sensitive to K~v~ Channel Blockers E-4031, XE991, and TEA
-----------------------------------------------------------------------------------

We then evaluated whether K~v~12.1 channels were sensitive to channel inhibitors that are widely used to attribute neuronal K^+^ currents to particular channel families. At concentrations generally applied to inhibit established target channels, human K~v~12.1 channels were insensitive to both E-4031 (20 μM), a specific inhibitor of K~v~11 channels (Supplementary Figures [2A,B](#SM1){ref-type="supplementary-material"}) ([@B50]), and XE991 (10 μM), a specific antagonist of neuronal K~v~7 (KCNQ) channels (Supplementary Figures [2D,E](#SM1){ref-type="supplementary-material"}) ([@B54]). K~v~12.1-mediated currents were also insensitive to E-4031 and XE991 concentrations up to 100 μM (Supplementary Figures [2C,F](#SM1){ref-type="supplementary-material"}). K~v~12.1 channels also were not affected by the broad-spectrum K^+^ channel inhibitor tetraethylammonium (TEA) at a concentration that completely inhibited K~v~7.2 channels (5 mM; Supplementary Figures [2G,H](#SM1){ref-type="supplementary-material"}) ([@B13]). However, K~v~12.1 channels were slightly inhibited by 50 and 100 mM TEA (*I*~50mM\ TEA~/*I*~Start~ = 0.90 ± 0.01; *I*~100mM\ TEA~/*I*~Start~ = 0.83 ± 0.01; *n* = 9; Supplementary Figure [2I](#SM1){ref-type="supplementary-material"}). Of note, low sensitivity of K~v~12.1 channels to E-4031 and TEA has been shown in an early report ([@B42]). In summary, E-4031, XE991 and TEA cannot be used to inhibit K~v~12.1 channels in native tissue, but may be used to isolate K~v~12.1 channel activity through inhibition of other K^+^ channels.

The Broad-Spectrum K^+^ Channel Antagonist 4-Aminopyridine (4-AP) Activates K~v~12.1
------------------------------------------------------------------------------------

We then tested whether human K~v~12.1 channels were sensitive to 4-AP, another established antagonist of several K~v~ families ([@B12]). Surprisingly, 4-AP at a concentration well in the range often used to isolate neuronal K^+^ currents (3 mM; e.g., [@B27]) increased K~v~12.1-mediated steady-state and tail currents within seconds (**Figures [3A](#F3){ref-type="fig"}--[C](#F3){ref-type="fig"}**). Current potentiation was the same for conditioning pulses of -60 and 0 mV, and 4-AP potentiated currents at all holding potentials positive to -60 mV (**Figure [3C](#F3){ref-type="fig"}**). 4-AP-dependent current increase was reversible within 2--3 min after washout of the drug (**Figure [3D](#F3){ref-type="fig"}**). 4-AP (3 mM) not only potentiated K~v~12.1-mediated currents, but also significantly shifted the voltage dependence of K~v~12.1 channels to hyperpolarized potentials (**Figure [3E](#F3){ref-type="fig"}**). Compared to control recordings measured before application of the substance, 3 mM 4-AP shifted *V*~h~ by -19.7 ± 1.7 mV (*n* = 7; *P* ≤ 0.001) and by -10.4 ± 1.5 mV (*n* = 7; *P* ≤ 0.001) after condition voltage pulses of -60 and 0 mV, respectively. Thus, the shift of *V*~h~ was significantly more pronounced for currents conditioned at -60 mV (*P* ≤ 0.01; c.f. **Figure [3E](#F3){ref-type="fig"}**).

![4-AP potentiates currents through human K~v~12.1 channels. **(A,B)** Representative recordings from a CHO cell transiently transfected with K~v~12.1 before (left) and after extracellular application of 3 mM 4-AP (right) after conditioning pulses of **(A)** --60 mV and **(B)** 0 mV. **(C)** 4-AP-dependent activation of K~v~12.1-mediated steady-state outward currents was independent on employed voltage protocols (summary of recordings as presented in **A,B**). 4-AP potentiated currents at all holding potentials positive to --60 mV. **(D)** 4-AP-dependent potentiation of K~v~12.1 currents was reversible, as current amplitudes returned to control levels within 2--3 min after removal of the substance \[shown are representative recordings under control conditions (gray), after application of 3 mM 4-AP (green) and at different time points (30, 90, and 150 s) after washout of 4-AP\]. **(E)** 3 mM 4-AP shifted the voltage dependence of human K~v~12.1 channels to hyperpolarized potentials (open squares) \[the panel shows Boltzmann fits to averaged data; data obtained from recordings as shown in **(A,B)**\]. **(F)** 4-AP activated K~v~12.1 channels in a dose-dependent manner. When pH of the extracellular solution was adjusted to 7.4 at higher 4-AP concentrations, the EC~50~ was about 2.1 mM and the Hill coefficient was about 0.8 (red trace). When pH of the solutions was not adjusted, the EC~50~ was about 3.1 and Hill coefficient was 0.9 (black trace). Parameters were derived from fits of averaged data to a Hill equation described in Section "Materials and Methods" (solid line represents fit; note that addition of 4-AP to 5 and 10 mM 4-AP increased the pH of the solution to 8.1 and 9.0, respectively). **(G)** Increasing the pH of the extracellular solution from 7.4 to 8.1 or 9.0 without addition of 4-AP did not increase K~v~12.1-mediated steady-state currents. In contrast, application of 5 mM or 10 mM 4-AP in extracellular solution without adjusting pH activated K~v~12.1 channels even more strongly than when pH of the solution was adjusted to pH 7.4. **(H)** Application of 3 mM 4-AP that does not change pH of the extracellular solution strongly potentiated K~v~12.1-mediated currents. Current potentiation through 3 mM 4-AP was further increased when the pH of the extracellular solution was increased to pH 8.1.](fnmol-11-00011-g003){#F3}

We then analyzed the dose-response relationship of 4-AP action on K~v~12.1 channels. As 5 and 10 mM 4-AP increased pH of the solution to about 8.1 and 9.0, respectively, we adjusted pH of these solutions to 7.4 after addition of 4-AP. Of note, 3 mM 4-AP or lower 4-AP concentrations did not alter the pH of the solution relevantly and thus no adjustment of pH was necessary. Under these experimental conditions, 4-AP potentiated K~v~12.1 currents in a concentration-dependent manner with an EC~50~ of about 2.1 and a Hill coefficient of about 0.8 (**Figure [3F](#F3){ref-type="fig"}**, *red trace*). In contrast, K~v~11.1 channels were inhibited by 4-AP with an IC~50~ of approximately 2.6 mM and a Hill coefficient of about 0.7 (Supplementary Figure [3](#SM1){ref-type="supplementary-material"}), consistent with previous reports (e.g., [@B35]). Thus, despite inverse effects of 4-AP on K~v~12.1 and K~v~11.1, the sensitivity of both channels to 4-AP was quite similar. When we applied 5 mM or 10 mM 4-AP without adjusting pH, we found that these concentrations activated K~v~12.1 channel even stronger than at physiological pH (**Figures [3F,G](#F3){ref-type="fig"}**). Without adjusting pH at higher concentrations, the EC~50~ was about 3.1 and the Hill coefficient was 0.9 (**Figure [3F](#F3){ref-type="fig"}**, *black trace*). As in line with a previous study ([@B19]) increasing pH of the extracellular solution from 7.4 to 8.1 or 9.0 without addition of 4-AP did not potentiate K~v~12.1-mediated steady-state currents (**Figure [3G](#F3){ref-type="fig"}**), these data suggested that 4-AP activated K~v~12.1 channels more efficiently at more alkaline pH. Indeed, increasing pH of the extracellular solution containing 3 mM 4-AP to 8.1 further increased K~v~12.1-mediated steady-state outward currents (**Figure [3H](#F3){ref-type="fig"}**).

K~v~12.1 Channels Are Also Activated by Isomeric Aminopyridines
---------------------------------------------------------------

Several other aminopyridines have been shown to inhibit voltage-gated K^+^ channels, albeit antagonistic efficiency of these substances was lower than that of 4-AP ([@B36]; [@B41]; [@B45]). We thus wondered whether we could identify isomeric aminopyridines that activated K~v~12.1, at best without affecting other K^+^ channels. We found that 2-aminopyridine (2-AP) and 3-aminopyridine (3-AP) potentiated K~v~12.1-mediated currents at a concentration close to the EC~50~ of 4-AP (3 mM) by about 20% (*P* ≤ 0.001) and 7% (*P* ≤ 0.001), respectively (**Figure [4](#F4){ref-type="fig"}**). At the same concentration 3,4-diaminopyridine (3,4-DAP; 3 mM) was ineffective. Hence, 2-AP (*P* ≤ 0.01) and 3-AP (*P* ≤ 0.001) activated K~v~12.1 channels significantly less than 4-AP mirroring efficacy of inhibition of other K^+^ channels by these substances ([@B36]; [@B41]; [@B45]).

![Activation of human K~v~12.1 channels by isomeric aminopyridines. **(A)** Representative whole cell currents through human K~v~12.1 channels elicited by voltage steps to 0 mV (voltage protocol as indicated). The upper panel shows effects of 2-AP (left), 3-AP (middle), or 3,4-DAP (right) on human K~v~12.1 channels. 4-AP was applied at the end of every recording for comparison of current potentiation (concentration of all substances was 3 mM). The lower panel displays chemical structures of 4-AP, 2-AP, 3-AP, and 3,4-DAP. **(B)** Summary of recordings as presented in **A** (steady-state outward currents at 0 mV were analyzed at the end of the activating pulse). At the same concentration (all 3 mM), 2-AP and 3-AP significantly potentiated K~v~12.1-mediated currents, albeit to a lower extent than 4-AP (^∗∗^*P* ≤ 0.01; ^∗∗∗^*P* ≤ 0.001).](fnmol-11-00011-g004){#F4}

NS1643, an Activator of K~v~11 Channels, Inhibits K~v~12.1 Channels
-------------------------------------------------------------------

We then turned to NS1643, a partial agonist of the K~v~11 channel family ([@B6]). As shown earlier (c.f. [@B14]), NS1643 (30 μM) slowed channel deactivation and potentiated K~v~11.1-mediated outward currents (**Figures [5A](#F5){ref-type="fig"}--[C](#F5){ref-type="fig"}**). In contrast, the same concentration of NS1643 (30 μM) completely inhibited K~v~12.1 channels with a time constant of 16.8 ± 2.6 s (*n* = 7; **Figures [5A](#F5){ref-type="fig"}--[C](#F5){ref-type="fig"}**). When we applied only 10 μM NS1643, a concentration close to the reported EC~50~ of NS1643 for activation of K~v~11.1 channels ([@B6]), K~v~12.1-mediated currents were reduced to 37.1 ± 4.1% of initial current amplitudes. Inhibition of currents by 10 μM was much slower than when 30 μM NS1643 was applied (*n* = 6; compare **Figure [5B](#F5){ref-type="fig"}** and Supplementary Figure [4](#SM1){ref-type="supplementary-material"}). We then analyzed voltage dependence of residual K~v~12.1 currents in the presence of 10 μM NS1643 (**Figures [5D](#F5){ref-type="fig"}--[F](#F5){ref-type="fig"}**): Application of NS1643 (10 μM) shifted *V*~h~ by +8.8 ± 2.9 mV (*n* = 6; *P* ≤ 0.05) and by +21.7 ± 5.2 mV (*n* = 6; *P* ≤ 0.01) after condition voltage pulses of -60 and 0 mV, respectively (**Figures [5D](#F5){ref-type="fig"}--[F](#F5){ref-type="fig"}**). At the same time, slope factors changed by +8.0 ± 1.5 mV (conditioning pulse of -60 mV; *n* = 6; *P* ≤ 0.05) and -1.8 ± 0.9 mV (conditioning pulse 0 mV; *n* = 6; *P* ≤ 0.01). Furthermore, NS1643 (10 μM) significantly accelerated deactivation of K~v~12.1 channels at hyperpolarized potentials (**Figures [5G,H](#F5){ref-type="fig"}**; *P* ≤ 0.05; *n* = 6).

![Human K~v~12.1 channels are inhibited by NS1643. **(A)** Representative recordings of recombinant K~v~11.1 (left) and K~v~12.1 (right) channels before (black) and after (colored) application of 30 μM NS1643 (voltage protocol as indicated). **(B)** Averaged time course of the amplitudes of outward currents mediated by K~v~11.1 (black) and K~v~12.1 (red) channels upon application of 30 μM NS1643. NS1643 activated K~v~11.1 channels \[as previously reported; ([@B6]; [@B14])\], but completely inhibited K~v~12.1 channels (data were derived from recordings as in **A**). **(C)** Summarized effects of NS1643 on K~v~11.1 and K~v~12.1 channels. 10 μM NS1643 did not completely inhibit K~v~12.1 channels allowing for further analysis of remaining currents. The time course of K~v~12.1 current inhibition by 10 μM NS1643 is shown in Supplementary Figure [4](#SM1){ref-type="supplementary-material"}. **(D--F)** Voltage dependence of K~v~12.1 channels changes through application of 10 μM NS1643. **(D)** Representative recordings of K~v~12.1 channels after conditioning potential of 0 mV before (top) and after (bottom) application of 10 μM NS1643 (for clarity only these recordings are shown). **(E)** 10 μM NS1643 significantly shifted voltage dependence of K~v~12.1 channels to depolarized potentials (solid lines represent Boltzmann fits to averaged data). **(F)** Shows averaged shifts of *V*~h~ (Δ*V*~h~) induced by 10 μM NS1643 for currents conditioned at --60 and 0 mV. **(G,H)** NS1643 significantly accelerated K~v~12.1 channel deactivation. **(G)** Representative normalized tail currents elicited at --120 mV after activation at --20 mV before (control, black) and after (red) application of 10 μM NS1643. **(H)** Shows averaged time constants of deactivation before and after application of NS1643 (10 μM) (^∗^*P* ≤ 0.05; ^∗∗^*P* ≤ 0.01).](fnmol-11-00011-g005){#F5}

Identification of K~v~12.1 Currents in Cells Expressing Different K^+^ Currents
-------------------------------------------------------------------------------

Our results suggested that voltage-clamp protocols designed to detect mode shift in combination with pharmacology using 4-AP or NS1643 should provide a robust approach for isolation of K~v~12.1-mediated currents in native cell types. As proof of principle, we sought to isolate K~v~12.1 channel activity in cells expressing different K^+^ channels (**Figure [6](#F6){ref-type="fig"}**). To this end, we co-expressed K~v~12.1 channels together with K~v~11.1 and typical neuronal K^+^ channels (K~v~7.2, K~v~7.3 and Kir2.1). In these experiments, CHO cells were transiently transfected with equal amounts of plasmid DNA encoding the channel subunits (see section "Materials and Methods" for details). We first analyzed whether we could isolate Kir2.1- and K~v~7-mediated currents in those cells. In all cells tested, we found large inward currents at hyperpolarized potentials and XE991-sensitive outward currents at depolarized potentials demonstrating expression of functional Kir2.1 and K~v~7 channels, respectively (Supplementary Figure [5](#SM1){ref-type="supplementary-material"}). As measure for abundance of K~v~11.1 and K~v~12.1 channels, we then tested whether we could detect mode shift of voltage dependence in the mix of K^+^ currents. As determined from whole cell currents, *V*~h~ was -6.7 ± 1.3 mV and -80.0 ± 2.1 mV after conditioning potentials of -60 and 0 mV, respectively (*n* = 7; **Figures [6A](#F6){ref-type="fig"}--[C](#F6){ref-type="fig"}**). Thus, mode shift of channels expressed in these cells (K~v~11.1 and K~v~12.1 channels) was readily detectable even among a complement of different voltage-dependent K^+^ channels. We next attempted to isolate K~v~12.1-mediated currents among the mixture of K^+^ channel by making use of the pharmacological profile established above. 4-AP (3 mM) shifted the voltage dependence of whole cell currents by -8.5 ± 0.9 mV (*n* = 7; *P* ≤ 0.001) and by -12.3 ± 2.3 mV (*n* = 7; *P* ≤ 0.05) to hyperpolarized potentials after conditioning voltages of -60 and 0 mV, respectively (**Figures [6B,C](#F6){ref-type="fig"}**). Thus, although being less pronounced than for K~v~12.1 channels alone (**Figure [6C](#F6){ref-type="fig"}**), the 4-AP-induced shift of voltage dependence was readily detectable in the mixed K^+^ current situation. At the same time, 4-AP (3 mM) potentiated whole cell currents elicited at -60 and 0 mV to about 210% and 140% of baseline amplitudes, respectively (**Figures [6A,D--F](#F6){ref-type="fig"}**). Finally, we applied 30 μM NS1643 (on top of 4-AP) to the same cells and found that the substance inhibited outward currents and inward tail currents (**Figures [6A,D,E](#F6){ref-type="fig"}**). NS1643 also slowed deactivation kinetics of remaining currents (c.f. **Figure [6A](#F6){ref-type="fig"}**) indicating that NS1643-sensitive and functional K~v~11.1 channels were expressed in these cells.

![Detection of K~v~12.1 channel activity in cells expressing various K^+^ currents. **(A)** Representative recordings of a CHO cell expressing different K^+^ channel subunits (K~v~7.2, K~v~7.3, K~v~11.1 and Kir2.1) together with K~v~12.1 under control conditions (left), upon application of 3 mM 4-AP (middle) and of 4-AP together with 30 μM NS1643 (right) (voltage protocol as indicated). **(B)** Voltage dependence of whole cell currents in cells expressing the mix of K^+^ channel subunits. *V*~h~ of whole cell currents was --6.7 ± 1.3 mV (black filled squares) after conditioning potential of --60 mV. When cells were held for 200 ms at a conditioning potential of 0 mV before the activation pulses, *V*~h~ of whole cell currents was --80.0 ± 2.1 mV (red filled squares). Application of 3 mM 4-AP shifted voltage dependence to hyperpolarized potentials for both conditioning potentials (open squares; graph displays Boltzmann fits to averaged data as solid lines). **(C)** 4-AP (3 mM)-induced shift of *V*~h~ to hyperpolarized potentials shown for cells expressing the mix of K^+^ channels (red squares) in comparison to cells expressing only K~v~12.1 (black circles). The 4-AP-induced shift of voltage dependence after conditioning voltage of --60 mV was smaller than in cells expressing only K~v~12.1 channels. Data for K~v~12.1 alone were derived from experiments also shown in **Figure [3E](#F3){ref-type="fig"}**. **(D,E)** Summary of time course and current amplitudes in cells expressing a mix of K^+^ channels during during application of 4-AP and NS1643 (together with 4-AP). **(D)** Representative current traces recorded in cells expressing a mix of K^+^ channels before (black), during application of 3 mM 4-AP (blue) and during application of 3 mM 4-AP together with 30 μM NS1643 (orange). **(E)** Averaged time course of current amplitudes upon application of 3 mM 4-AP and 30 μM NS1643 for CHO cells expressing K~v~12.1 channels alone (black) and the mix of K^+^ channels (red) (data obtained from recordings as presented in **D**). **(F)** Summarized 4-AP-induced potentiation of steady-state outward currents for cells expressing K~v~12.1 channels together with a mix of neuronal K^+^ channels. Data were derived from recordings as presented in **(D)**, and currents elicited at --60 mV and at 0 mV were analyzed.](fnmol-11-00011-g006){#F6}

Taken together, using abovementioned experimental protocols we could unequivocally identify properties of K~v~12.1 channels (mode shift, 4-AP and NS1643 sensitivity) among a mixture of K^+^ currents. These results therefore suggest that the same protocols may be used to assign K^+^ current components to K~v~12.1 channels in complex (native) cellular/neuronal settings.

Discussion
==========

The three members of the *ether-à-go-go*-like channel family of voltage-gated K^+^ channels (K~v~12.1-K~v~12.3) are predominantly expressed in neurons, as shown by mRNA transcripts in several brain areas including cerebral cortex and hippocampus ([@B29]; [@B49]; [@B37]; [@B57]), as well as in sympathetic ganglia ([@B42]). However, neuronal current components and their physiological relevance have been resolved for K~v~12.2 subunits exclusively: as demonstrated by application of a selective inhibitor, K~v~12.2 activity controls resting membrane potential and spontaneous firing of pyramidal neurons in hippocampus ([@B56]). Also, in K~v~12.2 knock-out mice it was shown that K~v~12.2 channels regulate hippocampal excitability ([@B56]) and may be important for processing of spatial working memory ([@B30]). However, it is not known whether K~v~12 channels mediate relevant currents in any other physiological system.

Here, we focused on recombinant human K~v~12.1 to identify distinct biophysical and pharmacological properties allowing for attribution of native currents to these channels.

Human K~v~12.1 Channels Exhibit Mode Shift of Activation
--------------------------------------------------------

Mode shift of activation was recently demonstrated for K~v~12.1 channel isoforms of humans and zebrafish heterologously expressed in *Xenopus laevis* oocytes ([@B25]; [@B9]). However, mode shift of these channels has not been characterized in mammalian cells in detail yet. We found that mode shift of human K~v~12.1 was readily induced by depolarized holding potentials between -60 and 0 mV and that it manifested by slowed channel deactivation and a striking shift of voltage dependence to hyperpolarized potentials. Deceleration of deactivation is generally considered a biophysical hallmark of mode shift, as channels undergo additional (time-consuming) transitions from this "relaxed" (metastable) open state into deactivation ([@B3]; [@B53]; [@B7]; [@B52]). Similar to K~v~11.1 ([@B47]) and zebrafish K~v~12.1 ([@B9]), mode shift of human K~v~12.1 channels manifested by a striking -60 mV shift of voltage dependence. Thus, mode shift-dependent hyperpolarizing shifts of voltage dependence were qualitatively and quantitatively comparable for these three ion channels. Of note, mode shift of K~v~12.1 channels was readily induced using different voltage protocols, albeit the extent of the hyperpolarizing shift of activation potentials varied considerably with duration of hyperpolarized voltage steps. This demonstrated high sensitivity of K~v~12.1 channels to the holding potential, but also highlighted that voltage dependence of native K~v~12.1 currents might also vary with the used voltage protocols. In contrast to zebrafish K~v~12.1 ([@B9]), activation of human K~v~12.1 channels did not exhibit prominent double exponential kinetics that might indicate transition into a more stable open conformation. However, human K~v~11.1 channels that beyond doubt exhibit mode shift do not display such kinetics neither ([@B47]; [@B11]). This indicates that either kinetics were masked by channel inactivation, or transition was too fast in the human channel isoforms.

Time course of transition into the relaxed state varies considerably between channels requiring depolarization for minutes in Na~v~ ([@B3]), seconds in *Shaker* ([@B32]) and some hundreds of milliseconds in K~v~11.1 channels ([@B34]). For human K~v~12.1, we found that also some hundreds of milliseconds of conditioning depolarization was sufficient for significant alterations of voltage dependence and kinetics. Thus, time course of development of K~v~12.1 mode shift was well in the range of that published for K~v~11.1 channels ([@B34]). As K~v~12.1 channels are highly sensitive to changes of the holding potential, voltage dependence of the channels strongly depends on the employed voltage protocols. In fact, such protocol differences could account for considerable variations in voltage dependence of K~v~12.1 channels reported in different studies (*V*~h~ close to 0 mV in [@B42];*V*~h~ of about -60 mV in [@B57]).

K~v~12.1 Channels Are Activated by 4-AP, an Established K~v~ Channel Inhibitor
------------------------------------------------------------------------------

4-AP is a rather selective blocker of voltage-gated K^+^ channels: At micromolar concentrations, it reversibly inhibits activity of K~v~1 and K~v~3 family members, but at higher concentrations (in the millimolar range) 4-AP also blocks other K~v~ channels (e.g., K~v~11) ([@B12]; [@B1]). Thus, it was somewhat surprising to find that 4-AP activates K~v~12.1 channels. As an early study mentioned potentiation of K~v~12.3 through 4-AP without, however, showing any recordings (named rELK1; [@B10]), such 4-AP sensitivity may constitute a general feature of the K~v~12 family.

Earlier, it was shown that currents through K~v~2.1 channels that are normally inhibited by 4-AP were potentiated by the substance, but only when K~v~6.4 subunits were co-expressed ([@B44]). As K~v~2.1 and K~v~6.4 co-assemble into functional channels (reviewed in [@B4]), this suggested that K~v~6.4 largely determined altered 4-AP sensitivity of the resulting heteromeric channels. 4-AP suppressed closed state inactivation of K~v~2.1/K~v~6.4 resulting in exclusive current potentiation of currents through those heteromers ([@B44]). In contrast, K~v~12.1 channels did not inactivate in our experiments, and thus 4-AP probably does not potentiate K~v~12.1-mediated currents through a similar mechanism. As 4-AP, in contrast to K~v~2.1/K~v~6.4 heteromers, also modulated voltage dependence of K~v~12.1, actions of 4-AP are probably even more complex for these channels. Interestingly, a recent study demonstrated 4-AP-dependent activation of K~v~7.4 channels ([@B20]) indicating that 4-AP-dependent activation of voltage-gated K^+^ channels may constitute a more frequent phenomenon than expected. However, further work is needed to elucidate whether other members of the K~v~ channel superfamily also exhibit this special 4-AP sensitivity.

Yet, we do not know whether 4-AP directly activates K~v~12.1 channels or whether an auxiliary subunit endogenously expressed in CHO cells confers 4-AP activation to K~v~12.1. Unfortunately, at present nothing is known about physiologically relevant interaction partners of K~v~12.1 channels. As K~v~ channels (with K~v~2.1 as exception) normally do not form functional channels with members of other K~v~ families, heteromerization of K~v~12.1 channels with another pore forming α subunit apart from K~v~12.2 or K~v~12.3 is quite unlikely ([@B57]). Accordingly, a mechanism as shown for K~v~2.1 is rather implausible, and it is hard to imagine how a non-pore-forming auxiliary subunit could reverse 4-AP sensitivity from inhibition to activation. Furthermore, any endogenously expressed auxiliary subunit would need to be expressed at high abundance to saturate overexpressed K~v~12.1 channels. Hence, a straightforward model proposes direct activation of K~v~12.1 channels through 4-AP. However, we want to point-out that we cannot exclude indirect actions on the channels at the moment.

NS1643, a "Specific" Activator of K~v~11 Channels, Inhibits K~v~12.1
--------------------------------------------------------------------

NS1643 is a well-characterized partial agonist of K~v~11 channels that slows deactivation, increases tail-current amplitude, and shifts voltage dependence of activation to hyperpolarized potentials and voltage dependence of C-type inactivation to depolarized potentials ([@B6]; [@B14]). At the same time, NS1643 exhibits weak antagonistic effects on K~v~11 channels as evident by an attenuation of drug-induced current increase at higher concentrations ([@B6]; [@B40]). K~v~11.3 channels are even inhibited by higher concentrations of NS1643. For K~v~12.1 channels, NS1643 accelerated deactivation, inhibited outward and tail currents and shifted voltage dependence of activation to depolarized potentials (c.f. **Figure [5](#F5){ref-type="fig"}**). Thus, NS1643 affected K~v~11 and K~v~12.1 channels exactly in opposite directions. Similar to K~v~11.3 channels, NS1643 increased slope factor of voltage dependence of K~v~12.1 channels, even though already at lower concentrations. This suggests that NS1643 similarly affects K~v~11 and K~v~12.1 channels, but antagonistic effects might dominate over activation for K~v~12.1. In line, the concentration range of NS1643 effects was similar for these channel isoforms ([@B6]). However, so far we cannot tell whether NS1643 also exhibits weak agonistic effects on K~v~12.1 channels or whether NS1643 binds to homologous regions in K~v~11 and K~v~12.1 channels.

Conclusion and Outlook
----------------------

As pharmacological tools and appropriate mouse models are currently missing, identification of native K~v~12.1-mediated currents critically depends on identification of unique biophysical and pharmacological properties. Indeed, native currents were successfully attributed to related K~v~10 and K~v~11 channels by exploiting their unique activation kinetics (c.f. Cole-Moore shift; e.g., [@B28]) or exclusive Na^+^ sensitivity and pharmacology ([@B17], [@B16]; [@B15]), respectively. Here, we present distinctive pharmacological properties, and straightforward experimental protocols that may be employed to isolate K~v~12.1 channel activity in native tissue. As mode shift readily manifested in cells expressing various neuronal K^+^ currents, this experimental protocol may be used to demonstrate expression of channels with mode shift in native cell types. In neurons expressing various K^+^ current components, such changes of voltage dependence may be easier to detect than associated changes of deactivation kinetics. Such experiments may not provide definite proof for K~v~12 channel expression. However, expression of mode shift may be employed together with expression analyses, Na^+^ sensitivity, activation through 4-AP and inhibition by NS1643 to narrow down (or exclude) contribution of K~v~12.1 channels to whole cell currents. Identification of the combination of these properties would provide strong evidence for expression and thus potential physiological relevance of K~v~12.1 channels.

Materials and Methods {#s1}
=====================

Cell Culture and Transfection
-----------------------------

Chinese hamster ovary (CHO) dhFR^-^ cells were maintained as previously reported ([@B24]). Cells were kept in MEM Alpha Medium supplemented with 10% fetal calf serum (FCS) and 1% penicillin/streptomycin (pen/strep) (all Invitrogen GmbH, Darmstadt, Germany) in a humidified atmosphere at 5% CO~2~ and 37°C. Transient transfection of cells was done with jetPEI transfection reagent (Polyplus Transfection, Illkirch, France). All experiments were performed 24--48 h after transfection at room temperature (22--25°C). The expression vectors used were: K~v~7.2-pBK-CMV (gene: human KCNQ2; UniProt accession number: [O43526](O43526)), K~v~7.3-pBK-CMV (human KCNQ3; O43525), K~v~7.4-pBK-CMV (human KCNQ4; P56696) K~v~11.1 (Erg1)-pcDNA3.1 (rat KCNH2; O08962), K~v~12.1(Elk1)-pcDNA3.1-IRESeGFP (human KCNH8; Q96L42), Kir2.1-pBK-CMV (human KCNJ2; P63252), and pEGFP-C1 (Addgene, Teddington, United Kingdom). For recordings presented in **Figure [6](#F6){ref-type="fig"}** and Supplementary Figure [5](#SM1){ref-type="supplementary-material"}, CHO cells were transiently transfected with identical amounts of plasmids encoding K~v~7.2, K~v~7.3, K~v~11.1, K~v~12.1, and Kir2.1 (0.6 μg of plasmid DNA for every subunit).

Electrophysiological Recordings
-------------------------------

Electrophysiological recordings were performed in the whole cell configuration with an Axopatch 200B amplifier (Molecular Devices, Union City, CA, United States) or an HEKA EPC10 USB patch clamp amplifier HEKA (Elektronik, Lambrecht, Germany) in voltage-clamp mode ([@B23]). All recordings were low-pass filtered at 2 kHz and sampled at 5 kHz. Currents were elicited by voltage protocols indicated in the figures. Dashed lines in representative recordings highlight zero current. Borosilicate glass patch pipettes (Sutter Instrument Company, Novato, CA, United States) were used with an open pipette resistance of 2--3 MΩ after back-filling with intracellular solution. Liquid junction potentials were not compensated (approximately -4 mV). Series resistance (*R*~s~) typically was below 6 MΩ and compensated throughout the recordings (80--90%). Whole cell currents are presented normalized to the cell capacitance (current density; pA/pF) or as normalized to baseline current amplitude (*I*/*I*~Start~). Extracellular solutions for most experiments contained (mM) 144 NaCl, 5.8 KCl, 1.3 CaCl~2~, 0.9 MgCl~2~, 0.7 NaH~2~PO~4~, 10 HEPES and 5.6 [D]{.smallcaps}-glucose, pH 7.4 (with NaOH), 305--310 mOsm/kg. In some experiments, NaCl in the extracellular solution was substituted by *N*-methyl-[D]{.smallcaps}-glucamine (NMDG; Sigma--Aldrich) (c.f. **Figure [2](#F2){ref-type="fig"}**). The standard intracellular solution contained (mM) 135 KCl, 2.41 CaCl~2~ (100 nM free Ca^2+^), 3.5 MgCl~2~, 5 HEPES, 5 EGTA, 2.5 Na~2~ATP, pH 7.3 (with KOH), 290--295 mOsm/kg ([@B55]).

Substances
----------

Tetraethylammonium (TEA, Sigma), NMDG (Sigma), 4-aminopyridine (≥99%; Sigma and Tocris Bioscience, Bristol, United Kingdom), 2-aminopyridine (2-AP; Sigma), 3-aminopyridine (3-AP; Sigma), 3,4-diaminopyridine (3,4-DAP; Sigma), 1,3-Bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS 1643, Tocris), 10,10-*bis*(4-Pyridinylmethyl)-9(10*H*)-anthracenone dihydrochloride (XE991, Tocris), and *N*-\[4-\[\[1- \[2-(6-Methyl-2-pyridinyl)ethyl\]-4-piperidinyl\]carbonyl\]phenyl\] methanesulfonamide dihydrochloride (E-4031, Tocris) were diluted in extracellular solution to concentrations indicated in "Results." All substances were applied locally via a glass capillary through a custom-made application system.

Note on 4-AP Solutions
----------------------

4-AP did not significantly change the pH of the extracellular solution at concentrations below 3 mM. After dilution of the substance, pH of the extracellular solution containing 5 mM or 10 mM 4-AP typically was about 8.1 or 9.0, respectively. As indicated in "Results," in some experiments the pH of solutions containing 5 and 10 mM 4-AP was adjusted to 7.4 after dilution of 4-AP. At the concentration applied in the present study (3 mM), isomeric aminopyridines did not change pH of the extracellular solution (c.f. **Figure [4](#F4){ref-type="fig"}**).

Data Analysis
-------------

Patch clamp recordings were analyzed with PatchMaster (HEKA) and IgorPro (Wavemetrics, Lake Oswego, OR, United States). Voltage dependence of activation was derived from tail current amplitudes using voltage protocols indicated: Tail currents were fitted with a two-state Boltzmann function with *I* = *I*~min~ + (*I*~max~ - *I*~min~)*/*(*1* + *exp*((*V* -*V*~h~)*/s*)), where *I* is current, *V* is the membrane voltage, *V*~h~ is the voltage at half maximal activation, and *s* describes the steepness of the curve. Results are shown as conductance-voltage curves, obtained by normalizing to (*I*~max~ -*I*~min~), obtained from fits to data of individual experiments. Time constants of deactivation were derived from double-exponential fits to deactivating current components at indicated potentials. For dose-response relations, current potentiation at 0 mV (normalized to baseline) was fitted to a Hill equation with *I*/*I*~b~ = *I*~b~ + (*I*~max~-*I*~b~)/(1 + (EC~50~/\[S\])^n~H~^), where *I* is the (normalized) current, *I*~b~ and *I*~max~ denote minimal and maximal currents at low and high drug concentrations, EC~50~ is the concentration at the half maximal effect, \[S\] is the drug concentration and *n*~H~ is the Hill coefficient ([@B22]).

Statistical Analysis
--------------------

Isolated cells under investigation were randomly assigned to different treatment groups. Data recordings and analysis for experiments presented were not performed in a blinded manner. For some experiments, single recordings were normalized to base line values individually to account for baseline variations between cells. Statistical analysis was performed using two-tailed Student's *t*-test/Wilcoxon--Mann--Whitney test, and when appropriate comparisons between multiple groups were performed with ANOVA followed by Dunnett test. Significance was assigned at *P* ≤ 0.05 (^∗^*P* ≤ 0.05, ^∗∗^*P* ≤ 0.01, ^∗∗∗^*P* ≤ 0.001). Data subjected to statistical analysis have *n* over 5 per group and data are presented as mean ± SEM. In electrophysiological experiments, *n* represents the number of individual cells and accordingly the number of independent experiments (no pseudo-replication).
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